Journal Mobile Options
Table of Contents
Vol. 12, No. 3, 2009
Issue release date: February 2009
Public Health Genomics 2009;12:170–179
(DOI:10.1159/000189630)

Pharmacogenomics and the Challenge of Health Disparities

Lee S.S.
To view the fulltext, log in and/or choose pay-per-view option

Individual Users: Register with Karger Login Information

Please create your User ID & Password





Contact Information











I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in

Abstract

This paper examines emerging technologies and recent research on population differences in pharmacogenomics and the perspectives of scientists, community advocates, policymakers, and social critics on the use of race as a proxy for genetic variation. The discussion focuses on how recent developments in genomic science impact social understandings of racial difference and the public health goal to eliminate ongoing health disparities among racially identified groups. This paper examines how factors such as governmental policies – requiring the use of racial and ethnic categories in genetic research and increasing interest in identifying untapped racial market niches by the pharmaceutical and biotechnology industries – and weak governmental oversight of race-based therapeutics converge to create an ‘infrastructure of racialization’ that may alter the vision of personalized medicine that has been so highly anticipated. This paper argues that significant public investment in pharmacogenomics requires careful consideration of the emerging discourse that tethers racial justice to notions of racial biology and discusses the social and ethical implications for the pendulum shift towards a geneticization of race in drug development.



Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

References

  1. Brave New Pharmacy. Time magazine January 15, 2001, http://www.time.com/time/magazine/article/0,9171,998963,00.html.
  2. Ginsburg GS, McCarthy JJ: Personalized medicine: revolutionizing drug discovery and patient care. Trends Biotechnol 2001;19:491–496.
  3. Goldstein DB, Tate SK, Sisodya SM: Pharmacogenetics goes genomic. Nat Rev 2003:4:937–947.
  4. Lindpaintner K: Pharmacogenetics and the future of medical practice. J Mol Med 2003:81:141–153.
  5. Taylor RE: Pharmacological and cultural considerations in alcohol treatment clinical trials: issues in clinical research related to race and ethnicity. Alcohol Clin Exp Res 2003;27:1345–1348.
  6. Lee SS: Race, distributive justice and the promise of pharmacogenomics: ethical considerations. Am J Pharmacogenomics 2003;3:385–392.
  7. Cooper RS, Kaufman JS, Ward R: Race and genomics. N Engl J Med 2003;348:1166–1170.
  8. Sankar P: MEDLINE definitions of race and ethnicity and their application to genetic research. Nat Genet 2003;34:119.
  9. Mordini E: Ethical considerations on pharmacogenomics. Pharmacol Res 2004;49:375–379.
  10. Kalow W: Pharmacogenetics and personalised medicine. Fundam Clin Pharmacol 2002;16:337–342.
  11. Lipton P: Pharmacogenetics: the ethical issues. Pharmacogenomics J 2003;3:14–16.
  12. E15 Draft Guidance Terminology on Pharmacogenomics. Center for Biologics Evaluation and Research. Food and Drug Administration 2007 http://www.fda.gov/Cder/guidance/7619dft.pdf.
  13. Conner S: Glaxo chief: our drugs do not work on most patients. The Independent December 8, 2003. http://www.independent.co.uk/news/science/glaxo-chief-our-drugs-do-not-work-on-most-patients-575942.html.
  14. Lazarou J, Pomeranz BH, Corey PN: Incidence of adverse reactions on hospitalized patients. A meta-analysis of prospective studies. JAMA 1998;279:1200–1205.
  15. Ernst FR, Grizzle AJ: Drug-related morbidity and mortality: updating the cost-of-illness model. J Am Pharm Assoc (Wash) 2001;41:192–199.
  16. March R, Cheeseman K, Doherty M: Pharmacogenomics – legal, ethical and regulatory considerations. Pharmacogenomics 2001;2:317–327.
  17. Veenstra DL, Higashi MK, Phillips KA: Assessing the cost-effectiveness of pharmacogenomics. AAPS PharmSci 2000;2:E29.
  18. Risch N, Burchard E, Ziv E, Tang H: Categorization of humans in biomedical research: genes, race and disease. Genome Biol 2002;3:comment2007.1–comment2007.12.

    External Resources

  19. Mehl B, Santell J: Projecting future drug expenditures – 2000. Am J Health Syst Pharm 2000;57:129–138.
  20. Tollyma P, Guy P, Altshuler J, Flanagan A, Steiner M: A revolution in R&D. Boston Consulting Group, Boston, 2001.
  21. Johnson JA, Bootman JL: Drug-related morbidity and mortality. A cost of illness model. Arch Intern Med 1995;155:1949–1956.
  22. Genentech, press release: Genentech Announces Full Year and Fourth Quarter 2005 Results, http://www.gene.com/gene/news/press-releases/display.do?method=detail&id=9287.
  23. Wertz DC: Ethical, social and legal issues in pharmacogenomics. Pharmacogenomics J 2003;3:194.
  24. Issa AM: Ethical perspectives on pharmacogenomic profiling in the drug development process. Nat Rev Drug Discov 2002;1:300–308.
  25. Webster A, Martin P, Lewis G, Smart A: Integrating pharmacogenetics into society: in search of a model. Nat Rev Genet 2004;5:663–669.
  26. Morley KI, Hall WD: Using pharmacogenetics and pharmacogenomics in the treatment of psychiatric disorders: some ethical and economic considerations. J Mol Med 2004;82:21–30.
  27. Emilien G, Ponchon M, Caldas C, Isacson O, Maloteaux JM: Impact of genomics on drug discovery and clinical medicine. QJM 2000;93:391–423.
  28. Rai AK: Pharmacogenomic interventions, orphan drugs, and distributive justice: the role of cost-benefit analysis. Soc Philos Policy 2002;19:246–270.
  29. Lee SS, Mountain J, Koenig BA: The meanings of ‘race’ in the new genomics: implications for health disparities research. Yale J Health Policy Law Ethics 2001;1:33–75.
  30. Roden DM, Altman RB, Benowitz NL, Flockhart DA, Giacomini KM, Johnson JA, Krauss RM, McLeod HL, Ratain MJ, Relling MV, Ring HZ, Shuldiner AR, Weinshilboum RM, Weiss ST; Pharmacogenetics Research Network: Pharmacogenomics: challenges and opportunities. Ann Intern Med 2006;145:749–757.
  31. Sillanpaa MJ, Auranen K: Replication in genetic studies of complex traits. Ann Hum Genet 2004;68:646–657.
  32. Sankar P, Cho M: Toward a new vocabulary of human genetic variation. Science 2002;298:1337–1338.
  33. Kleinbaum DG, Kupper LL, Morgenstern H: Epidemiologic Research: Principles and Quantitative Methods. Van Nostrand Reinhold, New York, 1982.
  34. Cardon LR, Palmer LJ: Population stratification and spourious allelic association. Lancet 2003;361:598–604.
  35. Solus JF, Arietta BJ, Harris JR, Sexton DP, Steward JQ, McMunn C, Ihrie P, Mehall JM, Edwards TL, Dawson EP: Genetic variation in eleven phase I drug metabolism genes in an ethnically diverse population. Pharmacogenomics 2004;7:895–931.

    External Resources

  36. Yasar U, Aklillu E, Canaparo R, Sandberg M, Sayi J, Roh HK, Wennerholm A: Analysis of CYP2C9*5 in Caucasian, Oriental and black-African populations. Eur J Clin Pharmacol 2002;58:555–558.
  37. Blaisdell J, Jorge-Nebert LF, Coulter S, Ferguson SS, Lee SJ, Chanas B, Xi T, Mohrenweiser H, Ghanayem B, Goldstein JA: Discovery of new potentially defective alleles of human CYP2C9. Pharmacogenetics 2004;8:527–537.

    External Resources

  38. Smedley B, Stith A, Nelson A: Unequal Treatment: Confronting Racial and Ethnic Disparities in Health Care. Washington, The National Academic Press, 2002.
  39. Cohn JN, Johnson G, Ziesche S, Cobb F, Francis G, Tristani F, Smith R, Dunkman WB, Loeb H, Wong M: A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med 1991;325:303–310.
  40. Taylor AL, Ziesche S, Yancy C, Carson P, D‘Agostino R Jr, Ferdinand K, Taylor M, Adams K, Sabolinski M, Worcel M, Cohn JN; African-American Heart Failure Trial Investigators: Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. N Engl J Med 2004;351:2049–2057.
  41. Kahn J: How a drug becomes ‘ethnic’: law, commerce, and the production of racial categories in Medicine. Yale J Health Policy Law Ethics 2004;4:1–46.

    External Resources

  42. Sankar P, Kahn J: BiDil: race medicine or race marketing? Health Aff (Millwood) 2005;W5:455–463.
  43. Lapu-Bula R, Quarshie A, Lyn D, Oduwole A, Pack C, Morgan J, Nkemdiche S, Igho-Pemu P, Onwuanyi A, Li R, Ofili E: The 894T allele of endothelial nitric oxide synthase gene is related to left ventricular mass in African Americans with high-normal blood pressure. J Natl Med Assoc 2005;97:197–205.
  44. Bloche MG: Race-based therapeutics. N Engl J Med 2004;351:2035–2037.
  45. Food and Drug Administration. 2005. FDA Guidance on the Collection of Race and Ethnicity Data in Clinical Trials, http://www.fda.gov/Cber/gdlns/racethclin.htm.
  46. Epstein S: Inclusion: the Politics of Difference in Medical Research. Chicago, University of Chicago Press, 2007.
  47. Satel S: Medicine’s Race Problem. Policy Review 110; 2002. http://www.hoover.org/publications/policyreview/3462856.html.
  48. McKillop T: Annual Meeting Shareholders Report, 2005.


Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50